143 related articles for article (PubMed ID: 7672793)
1. E-cadherin expression in papillary transitional cell carcinoma of the urinary bladder.
Ross JS; del Rosario AD; Figge HL; Sheehan C; Fisher HA; Bui HX
Hum Pathol; 1995 Sep; 26(9):940-4. PubMed ID: 7672793
[TBL] [Abstract][Full Text] [Related]
2. [The expression of the E-cadherin in human urinary bladder carcinoma].
Miyazaki J; Fujisawa M; Arakawa S; Kamidono S
Nihon Hinyokika Gakkai Zasshi; 1995 Jul; 86(7):1208-15. PubMed ID: 7637235
[TBL] [Abstract][Full Text] [Related]
3. E-cadherin expression in urothelial carcinoma in situ, superficial papillary transitional cell carcinoma, and invasive transitional cell carcinoma.
Sun W; Herrera GA
Hum Pathol; 2002 Oct; 33(10):996-1000. PubMed ID: 12395372
[TBL] [Abstract][Full Text] [Related]
4. E-cadherin cell-adhesion molecule expression as a diagnostic adjunct in urothelial cytology.
Ross JS; Cheung C; Sheehan C; del Rosario AD; Bui HX; Fisher HA
Diagn Cytopathol; 1996 Jun; 14(4):310-5. PubMed ID: 8725130
[TBL] [Abstract][Full Text] [Related]
5. [E-CD expression and its clinical significance in human bladder carcinoma].
Hao Y; Zhao C; Li X; Teng M
Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):459-61. PubMed ID: 11829888
[TBL] [Abstract][Full Text] [Related]
6. The significance of E-cadherin in transitional-cell carcinoma of the human urinary bladder.
Fujisawa M; Miyazaki J; Takechi Y; Arakawa S; Kamidono S
World J Urol; 1996; 14 Suppl 1():S12-5. PubMed ID: 8738404
[TBL] [Abstract][Full Text] [Related]
7. Expression of the CD44 cell adhesion molecule in urinary bladder transitional cell carcinoma.
Ross JS; del Rosario AD; Bui HX; Kallakury BV; Okby NT; Figge J
Mod Pathol; 1996 Aug; 9(8):854-60. PubMed ID: 8871928
[TBL] [Abstract][Full Text] [Related]
8. p130Cas, E-cadherin and β-catenin in human transitional cell carcinoma of the bladder: expression and clinicopathological significance.
Hu X; Ruan Y; Cheng F; Yu W; Zhang X; Larré S
Int J Urol; 2011 Sep; 18(9):630-7. PubMed ID: 21672035
[TBL] [Abstract][Full Text] [Related]
9. The relationship between the expression of E-cadherin and tumor recurrence and progression in high-grade stage T1 bladder urothelial carcinoma.
Erdemir F; Ozcan F; Kilicaslan I; Parlaktas BS; Uluocak N; Gokce O
Int Urol Nephrol; 2007; 39(4):1031-7. PubMed ID: 17340210
[TBL] [Abstract][Full Text] [Related]
10. E-cadherin expression in prostatic carcinoma biopsies: correlation with tumor grade, DNA content, pathologic stage, and clinical outcome.
Ross JS; Figge HL; Bui HX; del Rosario AD; Fisher HA; Nazeer T; Jennings TA; Ingle R; Kim DN
Mod Pathol; 1994 Oct; 7(8):835-41. PubMed ID: 7530850
[TBL] [Abstract][Full Text] [Related]
11. E-cadherin tissue expression and urinary soluble forms of E-cadherin in patients with bladder transitional cell carcinoma.
Shi B; Laudon V; Yu S; Dong D; Zhu Y; Xu Z
Urol Int; 2008; 81(3):320-4. PubMed ID: 18931551
[TBL] [Abstract][Full Text] [Related]
12. E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup.
Byrne RR; Shariat SF; Brown R; Kattan MW; Morton RA JR; Wheeler TM; Lerner SP
J Urol; 2001 May; 165(5):1473-9. PubMed ID: 11342899
[TBL] [Abstract][Full Text] [Related]
13. CD10 and E-cad expression in urinary bladder urothelial and squamous cell carcinoma.
Omran OM
J Environ Pathol Toxicol Oncol; 2012; 31(3):203-12. PubMed ID: 23339695
[TBL] [Abstract][Full Text] [Related]
14. E-cadherin expression as a prognostic factor in transitional cell carcinoma of the bladder after transurethral resection.
Khorrami MH; Hadi M; Gharaati MR; Izadpanahi MH; Javid A; Zargham M
Urol J; 2012; 9(3):581-5. PubMed ID: 22903481
[TBL] [Abstract][Full Text] [Related]
15. E-cadherin expression in bladder cancer using formalin-fixed, paraffin-embedded tissues: correlation with histopathological grade, tumour stage and survival.
Syrigos KN; Krausz T; Waxman J; Pandha H; Rowlinson-Busza G; Verne J; Epenetos AA; Pignatelli M
Int J Cancer; 1995 Dec; 64(6):367-70. PubMed ID: 8550236
[TBL] [Abstract][Full Text] [Related]
16. E-cadherin immunoreactivity correlates with recurrence and progression of minimally invasive transitional cell carcinomas of the urinary bladder.
Mahnken A; Kausch I; Feller AC; Krüger S
Oncol Rep; 2005 Oct; 14(4):1065-70. PubMed ID: 16142373
[TBL] [Abstract][Full Text] [Related]
17. The prognostic importance of e-cadherin and p53 gene expression in transitional bladder carcinoma patients.
Serdar A; Turhan C; Soner G; Cem SN; Bayram K; Damla BE; Erbil E
Int Urol Nephrol; 2005; 37(3):485-92. PubMed ID: 16307325
[TBL] [Abstract][Full Text] [Related]
18. Cyclooxygenase-2 expression in urinary bladder transitional cell carcinoma and its association with clinicopathological characteristics.
Tabriz HM; Olfati G; Ahmadi SA; Yusefnia S
Asian Pac J Cancer Prev; 2013; 14(8):4539-43. PubMed ID: 24083698
[TBL] [Abstract][Full Text] [Related]
19. Treatment with low-dose interferon-alpha restores the balance between matrix metalloproteinase-9 and E-cadherin expression in human transitional cell carcinoma of the bladder.
Slaton JW; Karashima T; Perrotte P; Inoue K; Kim SJ; Izawa J; Kedar D; McConkey DJ; Millikan R; Sweeney P; Yoshikawa C; Shuin T; Dinney CP
Clin Cancer Res; 2001 Sep; 7(9):2840-53. PubMed ID: 11555602
[TBL] [Abstract][Full Text] [Related]
20. [Expression of bcl-2 and p16 in transitional cell carcinoma of urinary bladder].
Leng J; Zhang Y; Yao X; Wen K
Zhonghua Wai Ke Za Zhi; 2000 Jan; 38(1):40-3. PubMed ID: 11831985
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
